Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.34 |
| ▸ | TNKS | O95271 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16726679 | 0.86 | MAP2K4 (0.42) | RORCKCNJ5KCNJ3RAB9A | |
| SCHEMBL16611299 | 0.85 | KCNJ5 (0.31) | TNKSPARP1TNKS2KCNJ5KCNJ3 | |
| SCHEMBL16611258 | 0.84 | KCNJ5 (0.35) | RORCKCNJ5KCNJ3NPSR1 | |
| SCHEMBL16611001 | 0.84 | MAP4K1 (0.38) | RORCKCNJ5KCNJ3MAPTKMT2A | |
| SCHEMBL16610975 | 0.83 | MAP2K4 (0.44) | RORCPARP1KCNJ5KCNJ3RAB9A | |
| SCHEMBL16610697 | 0.82 | RORC (0.38) | RORCKCNJ5KCNJ3MAPT | |
| SCHEMBL16611354 | 0.81 | PRKAB2 (0.38) | RORCKCNJ5KCNJ3MAPTKMT2A | |
| SCHEMBL16610777 | 0.81 | RORC (0.39) | RORCPARP1KCNJ5KCNJ3MAPT | |
| SCHEMBL16610718 | 0.79 | NPSR1 (0.42) | RORCKCNJ5KCNJ3GAANPSR1 | |
| SCHEMBL16726684 | 0.79 | KCNJ5 (0.34) | RORCKCNJ5KCNJ3KMT2APTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | RORC 538/4885TNKS 2897/4885PARP1 875/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | RORC 538/4885TNKS 2897/4885PARP1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.